ZYME enters the final days of August with an unusual combination: short sellers adding to positions at the fastest weekly pace in months, while options traders have swung to one of the most bullish readings of the past year.
The options signal is the most striking data point this week. Call demand has overwhelmed puts, driving the put/call ratio down to 0.13 — nearly three standard deviations below its 20-day average of 0.61. That is close to the 52-week low and a dramatic reversal from the 0.69-0.70 range that prevailed through most of early August. Whatever spooked the market on Tuesday — the stock fell 4.5% on August 25 — it does not appear to have shaken the conviction of options traders positioning for further upside.
Short interest tells a more complicated story. Bears have been rebuilding steadily, with short interest climbing to 6.1% of the free float — up 11.9% over the past week and roughly 9.4% on Tuesday alone. The daily FINRA figure corroborates this, with the official settlement count at 4.54 million shares and 8.5 days to cover. That is not a squeezed position, but it is a directional one. Yet the borrow market offers little support to the bear thesis: availability is extremely loose at 705%, well above even the 52-week low of 319%, and cost to borrow has eased to just 0.51% — down 5% on the week and 11% over the past month. Bears can build positions cheaply and easily. The lending market is not putting pressure on them. The tension, then, is that options traders are buying calls aggressively into a stock where short sellers are also adding, at a moment when borrow costs give neither camp a structural edge.
The Street has been decisively tilting toward the bulls. Multiple analysts raised price targets this week following what appears to have been a positive pipeline or data update. Citigroup nudged its target to $38 from $37 while holding a Buy. HC Wainwright lifted to $55 from $51, also Buy — the most aggressive target on the Street. Wells Fargo raised to $40 and B. Riley to $44, both Buy or equivalent. The consensus mean target is $41.42, implying roughly 51% upside to the current price of $27.47. Even the most cautious recent update — Citizens reiterating at $32 — sits above where the stock closed Tuesday. The bull case rests on zanidatamab's pivotal trial readouts and potential FDA approval for Ziihera-based combinations; bears flag the single-product revenue dependence, dilution risk, and the binary nature of clinical-stage timelines. The ORTEX short score has ticked up to 53.6, near its highest reading of the past two weeks, though the EPS surprise factor rank of 61 reflects that Zymeworks has been beating estimates more often than not.
Perceptive Advisors built a meaningful position as of the last 13F cycle, adding nearly 4 million shares to reach 5.9% of outstanding stock. EcoR1 Capital remains the dominant holder at 32.4%, unchanged. The concentrated ownership structure means institutional conviction — or a change in that conviction — has outsized price impact. On the insider side, the most recent data is from January 2026 and too stale to draw conclusions from.
The next formal catalyst is the Q3 earnings report on November 6. Between now and then, the stock's direction is likely to hinge on any pipeline updates or conference presentations, with the options market already positioned for a sharp move higher — and short sellers betting the rally from the past month runs out of road.
See the live data behind this article on ORTEX.
Open ZYME on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
